| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 13 Nov 2026 |
Form 4: Sheena Jonathan, Director
Sold 1,500 shares ($479K) |
| 10 Nov 2026 |
Form 4: Sheena Jonathan, Director
Sold 3,086 shares ($976K) · Sold 64 shares ($19.8K) |
| 12 Nov 2026 | FORM S-8 |
| 12 Nov 2026 | S-3ASR |
| 06 Nov 2026 | SCHEDULE 13G/A |
| 05 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
AUSTIN, Texas, November 5, 2026 /BUSINESS WIRE/ — Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the third quarter ended September 30, 2026. |
| 05 Nov 2026 | SCHEDULE 13G |
| 04 Nov 2026 |
Form 4: Sheena Jonathan, Director
Sold 112 shares ($44.8K) |
| 04 Nov 2026 |
Form 4: Rabinowitz Matthew, Director
Sold 748 shares ($299K) |
| 04 Nov 2026 |
Form 4: Rabinowitz Daniel, SEC. AND CHIEF LEGAL OFFICER
Sold 341 shares ($136K) |
| 04 Nov 2026 |
Form 4: Moshkevich Solomon, PRESIDENT, CLINICALDIAGNOSTICS
Sold 3,419 shares ($1.4M) |
| 04 Nov 2026 |
Form 4: Fesko John, PRESIDENT, CHIEF BUS. OFFICER
Sold 302 shares ($121K) |
| 04 Nov 2026 |
Form 4: Chapman Steven Leonard, Director
Sold 3,801 shares ($1.57M) |
| 04 Nov 2026 |
Form 4: Brophy Michael Burkes, CHIEF FINANCIAL OFFICER
Sold 325 shares ($130K) · Sold 470 shares ($184K) |
| 03 Nov 2026 | 144 |
| 02 Nov 2026 | 144 |
| 02 Nov 2026 | 144 |
| 02 Nov 2026 | 144 |
Loading...